The Life Sciences team advised Arvinas, Inc. (Nasdaq: ARVN) on an agreement with Bayer to jointly launch a new company to leverage Arvinas’ PROTAC® technology for agricultural applications. In addition, Bayer and Arvinas entered into an agreement to leverage Arvinas’ novel PROTAC® protein degrader technology to develop new human therapeutics for patients with cardiovascular, oncological and gynecological diseases. The overall series of arrangements includes over $110 million in upfront cash and committed funding for the human disease collaboration, the agricultural joint venture, and a direct equity investment by Bayer in Arvinas.
Arvinas is a biopharmaceutical company creating a new class of therapies to degrade disease-causing proteins. The multi-faceted deal will extend the application of targeted protein degradation to new therapeutic areas and outside human biology. It leverages Arvinas’ expertise in targeted protein degradation, a field the company has led since its founding in 2013, and Bayer’s decades of experience in developing both human therapies and innovative, sustainable agricultural technologies.